Help May Be On Its Way: 10% Of Worlds Population Suffers From Pain or Depression US Nuclear and Grapheton Develop Neural Technology
Los Angeles, CA. July 14, 2020 – US Nuclear Corp. (OTC: UCLE), working with a start-up company similar to Elon Musk’s ‘Neuralink’, Grapheton, is eager to announce how Grapheton’s neural stimulation technology can help treat chronic pain and depression. It is estimated that 500 million people suffer chronic pain worldwide, and 300 million people suffer depression worldwide, affecting more people than any other health burden and adding to suicide and drug addiction rates. These symptoms are mentally and financially devastating to the afflicted persons and their families. In fact, the total US economic burden of major depressive disorder is now estimated to be $210 billion per year*. Chronic pain and depression are extremely complex disorders that are incredibly hard to treat. Fortunately, deep brain stimulation is proving to be an effective emerging treatment, and Grapheton has made several significant advances and improvements to the technology to make it even more viable.
Deep brain stimulation involves the surgical implantation of tiny electrodes in your brain that send electrical signals to the areas of your brain where the problems (pain, depression, or movement disorders) originate. These electrical signals regulate the brain’s activity in that region which can relieve the symptoms.
Depression treatments can range from medications to lifestyle changes, therapy, or any combination of the above. Unfortunately, some medications just exacerbate the problem, and some people have treatment-resistant depression. Deep brain stimulation is emerging as an effective treatment solution for chronic and resistant depression and has been reported to improve mood, alleviate depression, and lead to an increase in quality of life.